HZICC：Unlocked potential: why global innovators choose Hangzhou
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured letters of intent totaling over RMB 2.5 billion. But his success extends beyond the competition. "As a Zhejiang native, Hangzhou's...
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end CMC platform SUZHOU, China, Nov. 28, 2025 /PRNewswire/ -- BioDlink, a global leader...
Angel Yeast’s 8,500-Ton Specialty Yeast Facility and New Brewing Microbial Pilot Platform Come Online
YICHANG, China, Nov. 28, 2025 /PRNewswire/ -- Angel Yeast (SH600298), a global leader in yeast and fermentation solutions, has begun trial production at its new specialty yeast project in the Baiyang Biotechnology Park, Yichang High‑tech Zone. The facility commenced material feeding on August 31 and, once fully ramped, will reach an annual...
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China’s innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug marketing approval from the China National Medical Products Administration (NMPA). This approval is for the treatment of relapsed or refractory Large B-Cell...
K-Beauty & K-MediTech Expo Malaysia 2025 Concludes Successfully, Strengthening Korea-Malaysia Collaboration Across Beauty and Healthcare Sectors
PENANG, Malaysia, Nov. 28, 2025 /PRNewswire/ -- K-Beauty Expo Malaysia 2025 and K-MediTech Expo Malaysia 2025, hosted by Gyeonggi Province and organised by KINTEX, have successfully concluded at the Penang Waterfront Convention Centre (PWCC) after a dynamic three-day showcase of Korea's leading beauty and medical innovations. Making their Malaysian debut, the dual expos drew thousands of visitors, buyers, healthcare...
Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
XI'AN, China, Nov. 28, 2025 /PRNewswire/ -- On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution. Combining high automation with high-sensitivity NAT reagents, the solution enables earlier detection of low-viral-load infections—an essential step in reducing transfusion-transmitted HIV and safeguarding patients who rely on safe...
OMRON Healthcare Surpasses 50 Million Nebulizers Sold
- Easing Burden of Respiratory Diseases Worldwide since 1978 - KYOTO, Japan, Nov. 28, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its nebulizers have surpassed 50 million units. This proud milestone underscores the company's long-standing commitment to...
Yale-Trained Neuroscientist Unveils “Digital Sunshine” Device, Merging Ancient Eastern Wisdom with Modern Brain Science to Revolutionize Sleep
Panbrain Lume Offers a Drug-Free Path to Deeper Sleep and Faster Sleep Onset in Just 8 Minutes, Now Live on Kickstarter NEW HAVEN, Conn., Nov. 28, 2025 /PRNewswire/ -- In a bold fusion of cutting-edge neuroscience and ancient Eastern wellness principles, Dr. Nailin Yao, a former Yale postdoctoral fellow in psychiatry, today announces the launch of Panbrain Lume. This...
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers. This approach represents a first-in-class...
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published in the journal of Annals of Oncology (Impact Factor: 65.4). This study provides the first evidence...
